Literature DB >> 25792531

Endoluminal Reconstruction for Nonsaccular Aneurysms of the Proximal Posterior Cerebral Artery with the Pipeline Embolization Device.

D W Zumofen1, M Shapiro2, T Becske2, E Raz3, M B Potts1, H A Riina1, P K Nelson4.   

Abstract

BACKGROUND AND
PURPOSE: Treatment options for nonsaccular posterior cerebral artery aneurysms include a range of surgical and endovascular reconstructive and deconstructive methods. However, no truly satisfactory treatment option is available to date for lesions arising from the P1 and P2 segments. The purpose of the present case series is to investigate both the efficacy and safety of the Pipeline Embolization Device in treating these challenging aneurysms.
MATERIALS AND METHODS: We present a series of 6 consecutive patients who underwent endoluminal reconstruction with the Pipeline Embolization Device for nonsaccular P1 or P2 segment aneurysms between January 2009 and June 2013.
RESULTS: Aneurysm location included the P1 segment in 2 patients and the P2 segment in 4 patients. Mean aneurysm diameter was 23 mm (range, 5-44 mm). Mean length of the arterial segment involved was 10 mm (range, 6-19 mm). Clinical presentation included mass effect in 4 patients and perforator stroke and subacute aneurysmal subarachnoid hemorrhage in 1 patient each. Endovascular reconstruction was performed by using 1 Pipeline Embolization Device in 5 patients and 2 overlapping Pipeline Embolization Devices in the remaining patient. Angiographic aneurysm occlusion was immediate in 1 patient, within 6 months in 4 patients, and within 1 year in the remaining patient. Index symptoms resolved in 4 patients and stabilized in the remaining 2. No new permanent neurologic sequelae and no aneurysm recurrence were recorded during the mean follow-up period of 613 days (range, 540-725 days).
CONCLUSIONS: Endovascular reconstruction with the Pipeline Embolization Device for nonsaccular aneurysms arising from the P1 and P2 segments compares favorably with historical treatment options in terms of occlusion rate, margin of safety, and neurologic outcome.
© 2015 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2015        PMID: 25792531      PMCID: PMC7965276          DOI: 10.3174/ajnr.A4261

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

1.  Acute vasogenic edema induced by thrombosis of a giant intracranial aneurysm: a cause of pseudostroke after therapeutic occlusion of the parent vessel.

Authors:  Dima Hammoud; Philippe Gailloud; Alessandro Olivi; Kieran J Murphy
Journal:  AJNR Am J Neuroradiol       Date:  2003 Jun-Jul       Impact factor: 3.825

2.  Dissecting aneurysms of the posterior cerebral artery: current endovascular/surgical evaluation and treatment strategies.

Authors:  Huan Wang; Rose Du; Joel Stary; Christos Gkogkas; Dong Kim; Arthur Day; Kai Frerichs
Journal:  Neurosurgery       Date:  2012-06       Impact factor: 4.654

3.  Flow diverters at and beyond the level of the circle of willis for the treatment of intracranial aneurysms.

Authors:  Silvia Pistocchi; Raphaël Blanc; Bruno Bartolini; Michel Piotin
Journal:  Stroke       Date:  2012-01-26       Impact factor: 7.914

4.  Proposed classification of nonatherosclerotic cerebral fusiform and dissecting aneurysms.

Authors:  T Mizutani; Y Miki; H Kojima; H Suzuki
Journal:  Neurosurgery       Date:  1999-08       Impact factor: 4.654

5.  Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial.

Authors:  Tibor Becske; David F Kallmes; Isil Saatci; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Christopher J Moran; Henry H Woo; Demetrius K Lopes; Aaron L Berez; Daniel J Cher; Adnan H Siddiqui; Elad I Levy; Felipe C Albuquerque; David J Fiorella; Zsolt Berentei; Miklós Marosfoi; Saruhan H Cekirge; Peter K Nelson
Journal:  Radiology       Date:  2013-02-15       Impact factor: 11.105

6.  Endovascular occlusion of the posterior cerebral artery in the treatment of p2 ruptured aneurysms.

Authors:  E Cotroneo; R Gigli; G Guglielmi
Journal:  Interv Neuroradiol       Date:  2007-09-13       Impact factor: 1.610

7.  The pipeline embolization device for the intracranial treatment of aneurysms trial.

Authors:  P K Nelson; P Lylyk; I Szikora; S G Wetzel; I Wanke; D Fiorella
Journal:  AJNR Am J Neuroradiol       Date:  2010-12-09       Impact factor: 3.825

8.  Very late thrombosis of flow-diverting constructs after the treatment of large fusiform posterior circulation aneurysms.

Authors:  J Klisch; A Turk; R Turner; H H Woo; D Fiorella
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

9.  Safety of the pipeline embolization device in treatment of posterior circulation aneurysms.

Authors:  T J Phillips; J D Wenderoth; C C Phatouros; H Rice; T P Singh; L Devilliers; V Wycoco; S Meckel; W McAuliffe
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-07       Impact factor: 3.825

10.  Endovascular treatment of posterior cerebral artery aneurysms using detachable coils.

Authors:  Hong Gee Roh; Sam Soo Kim; Heon Han; Hyun-Seung Kang; Won-Jin Moon; Hong Sik Byun
Journal:  Neuroradiology       Date:  2007-11-13       Impact factor: 2.804

View more
  3 in total

1.  Stent-assisted coil embolization of a recurrent posterior cerebral artery aneurysm following surgical clipping.

Authors:  Tomonori Takeshita; Tomoaki Nagamine; Kohei Ishihara; Yasuhiko Kaku
Journal:  Neuroradiol J       Date:  2016-12-08

2.  Flow diverters for the posterior inferior cerebellar artery aneurysms: A systematic review and a single-arm meta-analysis.

Authors:  Xiang Liu; Kunyang Bao; Wenzhang Luo; Weifeng Wan; Tangming Peng; Changren Huang
Journal:  Interv Neuroradiol       Date:  2021-09-14       Impact factor: 1.764

Review 3.  Natural history and management of posterior cerebral artery aneurysms: a systematic review and meta-analysis of individual patient data.

Authors:  Muhammed Amir Essibayi; Soliman H Oushy; Zafer Keser; Giuseppe Lanzino
Journal:  Neurosurg Rev       Date:  2022-10-12       Impact factor: 2.800

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.